Regen BioPharma, Inc. (RGBP)
OTCMKTS · Delayed Price · Currency is USD
0.0001
-0.0001 (-33.33%)
Aug 19, 2026, 2:36 PM EST
Regen BioPharma Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
| 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 | |
Revenue Growth | 0% | 0% | 0% | 0.44% | 37.57% | 55.63% |
Gross Profit | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 |
Selling, General & Admin | 0.82 | 0.56 | 0.5 | 0.71 | 0.3 | 0.34 |
Research & Development | 0.22 | 0.01 | 0.15 | 0.21 | 0.28 | 0.04 |
Operating Expenses | 1.04 | 0.58 | 0.65 | 0.92 | 0.58 | 0.37 |
Operating Income | -0.8 | -0.34 | -0.42 | -0.69 | -0.34 | -0.2 |
Interest Expense | -0.21 | -0.21 | -0.1 | -0.06 | -0.21 | -0.37 |
Interest & Investment Income | - | - | - | - | 0 | 0 |
Other Non Operating Income (Expenses) | -0.17 | -0.73 | -0.15 | 1.9 | 3 | -4.26 |
EBT Excluding Unusual Items | -1.19 | -1.27 | -0.67 | 1.16 | 2.45 | -4.83 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.03 | -1.16 |
Legal Settlements | - | - | - | - | - | -0.8 |
Other Unusual Items | - | - | - | 0 | -0.03 | 0.02 |
Pretax Income | -1.19 | -1.27 | -0.67 | 1.16 | 2.44 | -6.77 |
Net Income | -1.19 | -1.27 | -0.67 | 1.16 | 2.44 | -6.77 |
Preferred Dividends & Other Adjustments | - | - | - | 0.13 | 0.22 | - |
Net Income to Common | -1.19 | -1.27 | -0.67 | 1.02 | 2.23 | -6.77 |
Net Income Growth | - | - | - | -54.04% | - | - |
Shares Outstanding (Basic) | 232 | 24 | 8 | 7 | 6 | 4 |
Shares Outstanding (Diluted) | 232 | 24 | 8 | 7 | 6 | 4 |
Shares Change | 1222.06% | 186.14% | 16.21% | 12.79% | 56.19% | 113.61% |
EPS (Basic) | -0.01 | -0.05 | -0.08 | 0.14 | 0.36 | -1.68 |
EPS (Diluted) | -0.01 | -0.05 | -0.08 | 0.14 | 0.36 | -1.68 |
EPS Growth | - | - | - | -59.25% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -339.81% | -143.11% | -176.37% | -290.39% | -144.20% | -117.28% |
Profit Margin | -501.43% | -538.76% | -282.49% | 432.66% | 945.59% | -3951.79% |
EBIT | -0.8 | -0.34 | -0.42 | -0.69 | -0.34 | -0.2 |
EBIT Margin | - | -143.11% | -176.37% | -290.39% | -144.19% | -117.28% |
Revenue as Reported | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.17 |